GUCY1A1
Guanylate cyclase soluble subunit alpha-1
As of the edition of 20 October 2026, GUCY1A1 (guanylate cyclase soluble subunit alpha-1, UniProt Q02108) has 10 drugs tested at it and 9 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q02108
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 12
- Disease areas
- Heart and blood vessels; Lungs and airways; Infections; Cancer; Skin and connective tissue; Digestive system; Hormones; Mental health
- Registered trials of its drugs
- 188
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Methylene blue cation | Marketed | Phase 4 | Ends 2027 |
| Riociguat | Marketed | Phase 4 | Ends 2034 |
| Vericiguat | Marketed | Phase 4 | Ends 2032 |
| Praliciguat | Active | Phase 2 | none listed |
| Olinciguat | Went quiet | Phase 2 | none listed |
| Ataciguat | Active | Phase 3 | none listed |
| Cinaciguat | Stopped | Phase 2 | none listed |
| Runcaciguat | Stopped | Phase 2 | none listed |
| MQX-503 | Went quiet | Phase 2 | none listed |
| Pentaerythritol tetranitrate | Marketed | No phase stated | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 8 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| MediQuest Therapeutics | Route A |
The other 8 companies at GUCY1A1
In the product9 companies in all; 8 are not named here, and no score is.
See the 9 companies at GUCY1A1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.